0001108205-24-000055.txt : 20240523 0001108205-24-000055.hdr.sgml : 20240523 20240523161221 ACCESSION NUMBER: 0001108205-24-000055 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240521 FILED AS OF DATE: 20240523 DATE AS OF CHANGE: 20240523 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Duvall Diantha CENTRAL INDEX KEY: 0001696784 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30347 FILM NUMBER: 24978341 MAIL ADDRESS: STREET 1: C/O GENOCEA BIOSCIENCES, INC. STREET 2: 100 ACORN PARK DRIVE 5TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02140 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CURIS INC CENTRAL INDEX KEY: 0001108205 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 043505116 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 128 SPRING STREET STREET 2: BUILDING C, SUITE 500 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 617-503-6500 MAIL ADDRESS: STREET 1: 128 SPRING STREET STREET 2: BUILDING C, SUITE 500 CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 wk-form4_1716495126.xml FORM 4 X0508 4 2024-05-21 0 0001108205 CURIS INC CRIS 0001696784 Duvall Diantha 128 SPRING STREET BUILDING C - SUITE 500 LEXINGTON MA 02421 0 1 0 0 CFO 0 Employee stock option (right to buy) 11.62 2024-05-21 4 A 0 39000 11.62 A 2034-01-18 Common Stock 39000 39000 D This option grant, as disclosed in Curis Inc.'s 2024 proxy statement, was approved by the Compensation Committee of the Board of Directors of Curis, Inc. on January 19, 2024, contingent upon shareholder approval of Curis's Fifth Amended and Restated 2010 Stock Incentive Plan to, among other things, increase the number of shares authorized for issuance thereunder and increase the per participant limit on the number of shares subject to awards that can be granted annually to participants in the plan; and further provided that such option would not be exercisable and no common stock would be issued thereunder, if the Fifth Amended and Restated 2010 Plan was not approved by Curis's shareholders. On May 21, 2024, at the 2024 annual meeting of shareholders, Curis's shareholders approved the Fifth Amended and Restated 2010 Plan. The option grant described in this Form 4 filing vests as to 25% of the original shares on January 19, 2025 and as to an additional 6.25% of the original shares each successive quarter and until January 19, 2028. /s/ Diantha Duvall, Attorney-in-fact 2024-05-23